NOTE: As provided in LFC policy, this report is intended only for use by the standing finance committees of the legislature. The Legislative Finance Committee does not assume responsibility for the accuracy of the information in this report when used for other purposes.

The most recent FIR version (in HTML & Adobe PDF formats) is available on the Legislative Website. The Adobe PDF version includes all attachments, whereas the HTML version does not. Previously issued FIRs and attachments may be obtained from the LFC in Suite 101 of the State Capitol Building North.

# FISCAL IMPACT REPORT

SPONSOR:	Hurt	DATE TYPED:	3/3/03	HB	
SHORT TITLE: Prescription Drug Copa		g Copayments		SB	647
			ANALYST:		Wilson

#### APPROPRIATION

Appropriation Contained		Estimated Additional Impact		Recurring or Non-Rec	Fund Affected
FY03	FY04	FY03	FY04		
			See Narrative		

## SOURCES OF INFORMATION

**Responses Received From** 

Health Policy Commission (HPC) Board of Pharmacy (BP)

## SUMMARY

#### Synopsis of Bill

Senate Bill 647 enacts a new section of the New Mexico Drug, Device and Cosmetic Act requiring copayments for prescription drugs that are advertised directly to consumers. These new copayments are in addition to insurance copays, and will go to the drugs' manufacturer. The copayment will be 20% of the cost of the prescription drug.

SB 647 requires drug manufacturers to provide pharmacies on a monthly basis a list of prescription drugs advertised for which the advertising co-payment applies.

#### Significant Issues

SB 647 appears to be an attempt to curtail the advertising of drugs by forcing the consumer to pay out of his own pocket for these products.

# FISCAL IMPLICATIONS

It is not clear how the provisions of SB 647 will be enforced, but when this is clarified there will be some fiscal impact to the enforcing agency.

Senate Bill 647 -- Page 2

# POSSIBLE QUESTIONS

Does SB 647 apply to medicaid and medicare recipients?

DW/sb/njw